Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited. This change in substantial holding, marked by various transactions including securities on loan and rehypothecation, affects the company’s voting securities, potentially impacting shareholder dynamics and market perception. The cessation of JPMorgan’s substantial holding could influence Mesoblast’s market position and investor relations strategies.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on developing innovative cellular medicines. The company is known for its work in regenerative medicine, leveraging stem cell technology to treat a range of inflammatory and degenerative conditions. Mesoblast’s market focus is on delivering therapies that address unmet needs in areas such as cardiovascular diseases, inflammatory ailments, and immune-mediated conditions.
YTD Price Performance: 5.45%
Average Trading Volume: 123,813
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.19B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.
